Loftus E V EV - OmicsDI

Show results for

Unknown (13)
Metabolomics (2)
Proteomics (1)

Organisms

Homo sapiens (1)

Repository

MetaboLights (2)
pride (1)

Tissue

LN-229 cell (1)

Technology Type

Mass spectrometry (2)
Bottom-up proteomics (1)
Data-dependent acquisition (1)
Data-independent acquisition (1)
Mass Spectrometry (1)

Instrument Platform

Liquid Chromatography MS - Negative (LC-MS (Negative)) (1)
Liquid Chromatography MS - Positive (LC-MS (Positive)) (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2022 (1)
2021 (1)
2026 (1)

CHEBI ID

CHEBI:15756 (2)
CHEBI:15843 (2)
CHEBI:16359 (2)
CHEBI:16418 (2)
CHEBI:16466 (2)
CHEBI:16473 (2)
CHEBI:16525 (2)
CHEBI:16688 (2)
CHEBI:16814 (2)
CHEBI:170121 (2)
CHEBI:17689 (2)
CHEBI:28834 (2)
CHEBI:545687 (2)
CHEBI:69236 (2)
CHEBI:86255 (2)
CHEBI:100147 (1)
CHEBI:10018 (1)
CHEBI:100246 (1)
CHEBI:10025 (1)
CHEBI:10026 (1)
CHEBI:10072 (1)
CHEBI:10093 (1)
CHEBI:10101 (1)
CHEBI:10105 (1)
CHEBI:10106 (1)
CHEBI:10110 (1)
CHEBI:101278 (1)
CHEBI:10130 (1)
CHEBI:10136 (1)
CHEBI:101381 (1)

Metabolite Name

(20S)-17,20-dihydroxypregn-4-en-3-one (2)
Arachidonic acid (2)
Cholic acid (2)
Dehydroepiandrosterone sulfate (2)
Ecdysone (2)
Sphingosine-1-phosphocholine (2)
(+)-12-hydroxy-9Z-hexadecenoic acid (1)
(+)-Armillarin (1)
(+)-Erysotrine (1)
(+)-Scalarin (1)
(+)-Tephrorin B (1)
(+)-endo-beta-Bergamotene (1)
(+)-trans-C75 (1)
(+/-)-(Z)-2-(5-Tetradecenyl)cyclobutanone (1)
(+/-)-1-(4-Methylphenyl)ethanol (1)
(+/-)-11-Methylhexadecanoic acid (1)
(+/-)-17-HDoHE (1)
(+/-)-2,4,8-Trimethyl-7-nonen-2-ol (1)
(+/-)-2-Methylthiazolidine (1)
(+/-)-20-HDoHE (1)
(+/-)-Camphoric acid (1)
(+/-)-Dulciol E (1)
(+/-)-Methyl 5-acetoxyhexanoate (1)
(+/-)-Pelletierine (1)
(+/-)-Rollipyrrole (1)
(+/-)11-HDoHE (1)
(+/-)12,13-DiHOME (1)
(+/-)13-HpODE (1)
(+/-)5,6-EpETrE (1)
(+/-)5-HEPE (1)

Release Date

2020 (4)
2025 (2)
2024 (2)
2026 (1)
2022 (1)
2019 (1)
2018 (1)
2007 (1)

Lab affiliation

Edinburgh Cancer Research, CRUK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, UK (1)

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.

Not available

S-EPMC10988107 | biostudies-literature

UPLC-QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease Diagnosis

Identification of new biomarkers may help in the early diagnosis of inflammatory bowel disease (IBD). In this study, ultrahigh-performance liquid chromatography equipped with quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) was used to analyze the untargeted lipidomics and compare plasma l...

2021-10-18 | MTBLS1183 | MetaboLights

Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.

Not available

S-EPMC12459986 | biostudies-literature

Pervasive phenotypic effects of FBXO42 promoted by regulation of PP4 phosphatase

Abstract F-box proteins are the substrate recognition modules of the SCF (SKP1–Cullin–F-box) E3 ubiquitin ligase complex. FBXO42, an understudied member of this family, has recently emerged as a modulator of key cellular processes, including cell cycle progression, DNA damage response and glioma ste...

ORGANISM(S): Homo sapiens (Human)

2026-02-23 | PXD069593 | Pride

Mechanism of interventional effect and targets of Zhuyu Pill in regulating and suppressing colitis and cholestasis

Zhuyu pill (ZYP) is a traditional Chinese medicine prescription composed of two drugs, Coptis chinensis Franch. and Tetradium ruticarpum (A. Jussieu) T. G. Hartley, and is commonly used in the clinical treatment of diseases of the digestive system. However, the mechanism underly...

2022-11-02 | MTBLS4980 | MetaboLights

Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.

Not available

S-EPMC12795599 | biostudies-literature

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Not available

S-EPMC7026826 | biostudies-literature

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.

Not available

S-EPMC7496810 | biostudies-literature

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

Not available